Remimazolam Pilot for Office-Based Dental Sedation: Adverse Events, Awareness and Outcomes
In recent years, remimazolam has gained approval for use in adult procedural sedation in both the United Kingdom and the United States, potentially offering an alternative to conventional sedatives like propofol and midazolam for procedural sedation. However, there is a limited body of literature th...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/23/7308 |
| _version_ | 1797399999683756032 |
|---|---|
| author | Rudi Swart Sabine S. A. Maes David Cavanaugh Keira P. Mason |
| author_facet | Rudi Swart Sabine S. A. Maes David Cavanaugh Keira P. Mason |
| author_sort | Rudi Swart |
| collection | DOAJ |
| description | In recent years, remimazolam has gained approval for use in adult procedural sedation in both the United Kingdom and the United States, potentially offering an alternative to conventional sedatives like propofol and midazolam for procedural sedation. However, there is a limited body of literature that systematically reviews the outcomes of a remimazolam-alfentanil combination protocol for routine office-based dental procedures. The primary objective of this pilot study was to assess the occurrence of significant adverse events associated with the use of a remimazolam-alfentanil sedation protocol for adult dental procedures. Secondary outcomes included evaluating physiological responses, sedation effectiveness, patient and clinician satisfaction and the incidence of intraprocedural awareness. Notably, no significant adverse events were reported among the 25 adult subjects who received remimazolam and alfentanil, and all dental procedures were successfully completed. Patients and clinicians expressed high levels of satisfaction, and patients did not report any distressing memories associated with the dental procedure. These findings suggest that in a limited cohort, the remimazolam-alfentanil regimen appears to be well tolerated and effective for office-based dental procedures in adult patients, with a low risk of adverse events, acceptable hemodynamic effects, rapid onset and recovery and minimal intraoperative awareness. This study provides valuable insights into the potential use of the remimazolam-alfentanil combination in dental sedation practice. |
| first_indexed | 2024-03-09T01:49:13Z |
| format | Article |
| id | doaj.art-beca8cf2bbe84100acad352a218c63f8 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T01:49:13Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-beca8cf2bbe84100acad352a218c63f82023-12-08T15:19:19ZengMDPI AGJournal of Clinical Medicine2077-03832023-11-011223730810.3390/jcm12237308Remimazolam Pilot for Office-Based Dental Sedation: Adverse Events, Awareness and OutcomesRudi Swart0Sabine S. A. Maes1David Cavanaugh2Keira P. Mason3Advanced Sedation Ltd., London CM4 0EG, UKDepartment of Anesthesia, University Hospital Antwerp, 2650 Edegem, BelgiumBoston Biostatistical Consulting, North Reading, MA 01864, USADepartment of Anesthesia, Critical Care and Pain Medicine, Boston Children’s Hospital, Boston, MA 02115, USAIn recent years, remimazolam has gained approval for use in adult procedural sedation in both the United Kingdom and the United States, potentially offering an alternative to conventional sedatives like propofol and midazolam for procedural sedation. However, there is a limited body of literature that systematically reviews the outcomes of a remimazolam-alfentanil combination protocol for routine office-based dental procedures. The primary objective of this pilot study was to assess the occurrence of significant adverse events associated with the use of a remimazolam-alfentanil sedation protocol for adult dental procedures. Secondary outcomes included evaluating physiological responses, sedation effectiveness, patient and clinician satisfaction and the incidence of intraprocedural awareness. Notably, no significant adverse events were reported among the 25 adult subjects who received remimazolam and alfentanil, and all dental procedures were successfully completed. Patients and clinicians expressed high levels of satisfaction, and patients did not report any distressing memories associated with the dental procedure. These findings suggest that in a limited cohort, the remimazolam-alfentanil regimen appears to be well tolerated and effective for office-based dental procedures in adult patients, with a low risk of adverse events, acceptable hemodynamic effects, rapid onset and recovery and minimal intraoperative awareness. This study provides valuable insights into the potential use of the remimazolam-alfentanil combination in dental sedation practice.https://www.mdpi.com/2077-0383/12/23/7308remimazolamalfentanilsedationdental sedationoffice-based sedationsafety |
| spellingShingle | Rudi Swart Sabine S. A. Maes David Cavanaugh Keira P. Mason Remimazolam Pilot for Office-Based Dental Sedation: Adverse Events, Awareness and Outcomes Journal of Clinical Medicine remimazolam alfentanil sedation dental sedation office-based sedation safety |
| title | Remimazolam Pilot for Office-Based Dental Sedation: Adverse Events, Awareness and Outcomes |
| title_full | Remimazolam Pilot for Office-Based Dental Sedation: Adverse Events, Awareness and Outcomes |
| title_fullStr | Remimazolam Pilot for Office-Based Dental Sedation: Adverse Events, Awareness and Outcomes |
| title_full_unstemmed | Remimazolam Pilot for Office-Based Dental Sedation: Adverse Events, Awareness and Outcomes |
| title_short | Remimazolam Pilot for Office-Based Dental Sedation: Adverse Events, Awareness and Outcomes |
| title_sort | remimazolam pilot for office based dental sedation adverse events awareness and outcomes |
| topic | remimazolam alfentanil sedation dental sedation office-based sedation safety |
| url | https://www.mdpi.com/2077-0383/12/23/7308 |
| work_keys_str_mv | AT rudiswart remimazolampilotforofficebaseddentalsedationadverseeventsawarenessandoutcomes AT sabinesamaes remimazolampilotforofficebaseddentalsedationadverseeventsawarenessandoutcomes AT davidcavanaugh remimazolampilotforofficebaseddentalsedationadverseeventsawarenessandoutcomes AT keirapmason remimazolampilotforofficebaseddentalsedationadverseeventsawarenessandoutcomes |